Prostaglandin analog + carbonic anhydrase inhibitor + beta-blocker combination

25 marketed 16 in Phase 3 1 in Phase 1

This page covers all Prostaglandin analog + carbonic anhydrase inhibitor + beta-blocker combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Prostaglandin F receptor (FP receptor); carbonic anhydrase II; beta-adrenergic receptors, Beta-2 adrenergic receptor (timolol); carbonic anhydrase II (dorzolamide), Carbonic anhydrase II; Beta-adrenergic receptors (β1 and β2).

Targets

Prostaglandin F receptor (FP receptor); carbonic anhydrase II; beta-adrenergic receptors · Beta-2 adrenergic receptor (timolol); carbonic anhydrase II (dorzolamide) · Carbonic anhydrase II; Beta-adrenergic receptors (β1 and β2) · Carbonic anhydrase II · Carbonic anhydrase 2 · Carbonic anhydrase (acetazolamide component); oxygen delivery and airway pressure modulation (supportive components) · Carbonic anhydrase · Na-K-2Cl cotransporter (furosemide); carbonic anhydrase (acetazolamide) · Carbonic anhydrase 1 · Carbonic anhydrase II, beta-2 adrenergic receptor, alpha-2A adrenergic receptor, prostaglandin F receptor

Marketed (25)

Phase 3 pipeline (16)

Phase 1 pipeline (1)

Patent intelligence